{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=6",
    "query": {
      "intervention": "Intermediate dose",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 2633,
    "total_pages": 264,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T05:54:20.580Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01828697",
      "title": "Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Deep Venous Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Low dose nadroparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose nadroparin",
          "type": "DRUG"
        },
        {
          "name": "Low dose enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Low dose dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Fixed low dose tinzaparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose tinzaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 1110,
      "start_date": "2013-04-24",
      "completion_date": "2021-10-31",
      "has_results": false,
      "last_update_posted_date": "2022-05-26",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828697"
    },
    {
      "nct_id": "NCT06180980",
      "title": "A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-01-04",
      "completion_date": "2021-03-08",
      "has_results": true,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06180980"
    },
    {
      "nct_id": "NCT05375903",
      "title": "A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer",
        "NMIBC",
        "Carcinoma in Situ of Bladder",
        "Bladder Cancer",
        "Urothelial Carcinoma Bladder",
        "Urothelial Carcinoma Recurrent"
      ],
      "interventions": [
        {
          "name": "UGN-301",
          "type": "DRUG"
        },
        {
          "name": "UGN-201",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2022-06-01",
      "completion_date": "2026-01-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375903"
    },
    {
      "nct_id": "NCT02946879",
      "title": "Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leber Congenital Amaurosis (LCA)",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Retinal Diseases"
      ],
      "interventions": [
        {
          "name": "AAV OPTIRPE65",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MeiraGTx UK II Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "3 Years to 100 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-11",
      "completion_date": "2023-07",
      "has_results": false,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02946879"
    },
    {
      "nct_id": "NCT06402968",
      "title": "Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Intracerebral Hemorrhage",
        "Stroke",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Clevidipine Injection",
          "type": "DRUG"
        },
        {
          "name": "Alternate IV Antihypertensive Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zeenat Qureshi Stroke Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1018,
      "start_date": "2024-06-01",
      "completion_date": "2028-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 20,
      "location_summary": "Irvine, California • Lancaster, California • Palo Alto, California + 17 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06402968"
    },
    {
      "nct_id": "NCT01318915",
      "title": "Research Study of ATG and Rituximab in Renal Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Renal Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2011-07-25",
      "completion_date": "2017-08-25",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01318915"
    },
    {
      "nct_id": "NCT00545168",
      "title": "Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediculus Capitis Infestation"
      ],
      "interventions": [
        {
          "name": "Spinosad",
          "type": "DRUG"
        },
        {
          "name": "Permethrin 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ParaPRO LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 480,
      "start_date": "2007-09",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2012-10-11",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 6,
      "location_summary": "Ormond Beach, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Ormond Beach",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Council Bluffs",
          "state": "Iowa"
        },
        {
          "city": "Corpus Christi",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00545168"
    },
    {
      "nct_id": "NCT04520685",
      "title": "CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Oral cannabidiol 100mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 86,
      "start_date": "2021-12-15",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04520685"
    },
    {
      "nct_id": "NCT00983515",
      "title": "Drug-Drug Interaction Between Colchicine and Ritonavir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Colchicine",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mutual Pharmaceutical Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-07",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2009-10-15",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 1,
      "location_summary": "East Grand Forks, Minnesota",
      "locations": [
        {
          "city": "East Grand Forks",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983515"
    },
    {
      "nct_id": "NCT00067015",
      "title": "Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "goserelin acetate",
          "type": "DRUG"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2003-05",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2015-12-22",
      "last_synced_at": "2026-10-24T05:54:20.580Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00067015"
    }
  ]
}